Kewaunee Scientific Q1 Sales Fall 6.7% as Life Sciences Demand Weakens
KEQU is trading near its 52-week low of $33.273 (2.2% above the low).
Summary
Kewaunee Scientific's fiscal Q1 sales dropped 6.7% to $66.32 million, with diluted EPS falling to $0.58 from $1.04 a year ago. The decline was driven by lower LPG sales and manufacturing volumes in the life sciences market. International profitability improved due to higher-margin projects, but corporate results included a one-time compensation expense from settling long-term incentive awards in cash. Management noted extended project award and release timelines amid geopolitical and economic uncertainty. This follows a strong FY2026 with 17.3% sales growth, making the Q1 reversal a notable shift. The stock is trading near its 52-week low, reflecting investor concern over near-term demand.
At the time of this announcement, KEQU was trading at $34.00 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $100.5M. The 52-week trading range was $33.27 to $57.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.